Drug Trial Radar · NCT07681271
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Dec 7, 2027
Study completion Dec 7, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.
Conditions
- Papulopustular Rosacea
Interventions
LOU064Drug
LOU064 administered by oral route
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in facial inflammatory lesion countTime frame: Baseline, Week 16
Locations
17 sites in 9 countries. Site status is shown where the registry gives one.
Three A Research
El Paso, Texas · Recruiting
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Markham, Ontario, Canada · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Hamburg, Germany · Recruiting
Novartis Investigative Site
Tübingen, Germany · Recruiting
Novartis Investigative Site
Cona, FE, Italy · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Icheon, South Korea · Recruiting
Novartis Investigative Site
Dongjak Gu, Seoul, South Korea · Recruiting
Novartis Investigative Site
Córdoba, Spain · Recruiting
Novartis Investigative Site
Granada, Spain · Recruiting
Novartis Investigative Site
Santiago de Compostela, A Coruna, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.